Equity

Health Sciences

Focused on investing in scientific and technological advances in health care

3D render of a medical background with DNA strand

Overview

  • Growth investment style that employs bottom-up, analyst-driven stock selection based on proprietary fundamental research and investment insights
  • Focus on durability/sustainability of growth rather than absolute growth rates
  • We believe new growth opportunities and significant alpha generation can result from correct analysis of new product opportunities

Characteristics & Performance

Composite Inception

6/30/1999

Strategy AUM

$2.0 Billion as of 6/30/26

Benchmark

S&P Health Care Index

Holdings Range

Typically 50 – 80, +/- 15 securities

Past performance does not guarantee future results. Inception of Health Sciences Equity Composite: 6/30/99. Source: Jennison and S&P Global. Gross of fee performance is presented before custodial and Jennison’s actual advisory fees but after transaction costs. *For periods prior to 11/1/13, net of fee performance is presented net of Jennison’s actual advisory fees and transaction costs. For periods beginning 11/1/13, net of fee performance reflects the deduction of a model fee. It is net of transaction costs and is calculated based on the highest tier of the fee schedule in effect for the respective period (1.00%), which may not reflect the actual historical fees applied to accounts in the Composite.

Characteristics are intended to provide a general illustration of the investment strategy and considerations used by Jennison in managing that strategy during normal market conditions and may change over time. Characteristics do not represent actual portfolio guidelines, which are negotiated with clients.

Performance results are calculated in US dollars and reflect reinvestment of dividends and other earnings. Periods greater than one year are annualized. Please refer to the GIPS presentation, which includes fee information and criteria for composite performance creation.

Available Vehicles

Institutional Separate Account

US Mutual Fund

Investment Team

Daniel Matviyenko

Managing Director

Debra Netschert

Managing Director

Cyrus Amoozegar, MD, PhD

Principal

Cynthia Chen, PhD

Principal

|

Biotechnology

Abhijith “Jith” Eswarappa

Managing Director

|

Therapeutics

Jeffrey T. McCarthy

Managing Director

Discuss Health Sciences Opportunities